Johnson & Johnson earnings beat estimates on strong cancer drug sales
- Posted on April 15, 2025
- By Business News Today
- 2 Views
Johnson & Johnson earnings beat estimates on strong cancer drug sales
Johnson & Johnson's first-quarter revenue and profit exceeded Wall Street expectations, driven by strong cancer drug sales. The company raised its 2025 sales forecast, factoring in the acquisition of schizophrenia drug Caplyta.
